Sensipar (Cinacalcet HCl) Patent Expiration, LOE Window & CMS Spending

Sensipar (Cinacalcet HCl) by Amgen: FDA Orange Book LOE 2026-09-22, 9 AB generics, $9.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmgen
FDA Application & PathwayN021688 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-09-22
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors9
2024 CMS Total Public Spend$9.3M
2024 Medicare Part D Spend$1.3M
2024 Medicaid Spend$8.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.